(Q44542878)

4 December 2017

title

Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification (English)

1 reference

4 December 2017

Roland F Staack

1

1 reference

4 December 2017

Gregor Jordan

series ordinal

2

1 reference

4 December 2017

Julia Heinrich

series ordinal

3

1 reference

4 December 2017

publication date

1 February 2012

1 reference

4 December 2017

1 reference

4 December 2017

volume

4

1 reference

4 December 2017

issue

4

1 reference

4 December 2017

page(s)

381-395

1 reference

Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Therapeutic monoclonal antibody concentration monitoring: free or total?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

PK-PD modeling of protein drugs: implications in assay development

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Application and interpretation of free and total drug measurements in the development of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Critical ligand binding reagent preparation/selection: when specificity depends on reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Key elements of bioanalytical method validation for macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Bioanalytical method validation for macromolecules in support of pharmacokinetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Widely varying TNF-alpha levels in patients with myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.11.321

21 January 2018

Identifiers

DOI

10.4155/BIO.11.321

1 reference

4 December 2017

1 reference